Gianna Musettini
Ospedale di Livorno(IT)Azienda Usl Toscana Centro(IT)
Publications by Year
Research Areas
Pancreatic and Hepatic Oncology Research, Colorectal Cancer Treatments and Studies, Cancer Genomics and Diagnostics, Gastric Cancer Management and Outcomes, Hepatocellular Carcinoma Treatment and Prognosis
Most-Cited Works
- → Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data(2015)60 cited
- → HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer(2020)51 cited
- → First‐line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors(2016)46 cited
- → Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial(2019)36 cited
- → Impact of a supportive care service for cancer outpatients: management and reduction of hospitalizations. Preliminary results of an integrated model of care(2016)24 cited
- → The Emerging Role of Liquid Biopsy in Diagnosis, Prognosis and Treatment Monitoring of Pancreatic Cancer(2018)23 cited
- → EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas(2017)19 cited
- → Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan(2019)18 cited
- → Nab-paclitaxel (Nab-P) and gemcitabine (G) as first-line chemotherapy (CT) in advanced pancreatic cancer (APDAC) elderly patients (pts): A “real-life” study.(2015)17 cited
- → Second-Line Therapy for Advanced Pancreatic Cancer: Evaluation of Prognostic Factors and Review of Current Literature(2016)17 cited